Europe
Acacia Pharma Group plc announces its unaudited results for the nine months to 30 September 2018 to provide an update on current trading and its cash position.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Risk factors of type 2 diabetes and cardiovascular disease accumulate in children who have poor aerobic fitness, a new study from the University of Eastern Finland shows.
Formulation issues cause significant drug project delays and project failures, as experienced by 60% of survey participants.
Advancing proprietary pipeline; solid progress in partnered programs
Secarna’s proprietary antisense oligonucleotide platform LNAplusTM to be combined with MetP Pharma’s nasal drug delivery technology to develop novel treatment options for neurodegenerative diseases
Extra funding for strategic move into downstream formulation and fill finish capabilities and full exploitation of Lock-Release as new ADC manufacturing paradigm
Novartis has been on something of a housecleaning binge since Vasant (Vas) Narasimhan took over the chief executive officer position from Joseph Jimenez in January of this year. On October 30, Novartis indicated it planned to abandon approximately 20 percent of its research projects.
AbbVie presented additional data from two Phase III clinical trials in women with uterine fibroids. In a big news week for the company, what else is AbbVie up to?
Boehringer Ingelheim and Epizyme signed a global collaboration deal to identify, develop and market cancer therapies. The deal could exceed $300 million.
PRESS RELEASES